drugset / Trial / NCT00411892

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892

Phase 3 Terminated 196 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.

Timeline

Start
2006-11-29
Primary completion
2008-03-18
Completion
2008-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled
Subject Pioglitazone Small molecule 45 mg